| Global burden of cardiovascular diseases and risks, 1990-2022 GA Mensah, V Fuster, CJL Murray, GA Roth, ... Journal of the American College of Cardiology 82 (25), 2350-2473, 2023 | 80 | 2023 |
| Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the … AE Schumacher, HH Kyu, A Aali, C Abbafati, J Abbas, ... The Lancet 403 (10440), 1989-2056, 2024 | 28 | 2024 |
| Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the … M Naghavi, KL Ong, A Aali, HS Ababneh, YH Abate, C Abbafati, ... The Lancet 403 (10440), 2100-2132, 2024 | 17 | 2024 |
| Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 JD Steinmetz, KM Seeher, N Schiess, E Nichols, B Cao, C Servili, ... The Lancet Neurology 23 (4), 344-381, 2024 | 17 | 2024 |
| Investigating the effects of bark extract and volatile oil of Pinus eldarica against cisplatin-induced genotoxicity on HUVECs cell line A Sharifan, M Etebari, B Zolfaghari, M Aliomrani Toxicology Research 10 (2), 223-231, 2021 | 16 | 2021 |
| Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, ... The Lancet 403 (10440), 2204-2256, 2024 | 4 | 2024 |
| Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease … M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, ... The Lancet 403 (10440), 2162-2203, 2024 | 4 | 2024 |
| Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, ... The Lancet 403 (10440), 2057-2099, 2024 | 4 | 2024 |
| Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in … AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, ... The Lancet 403 (10440), 2133-2161, 2024 | 2 | 2024 |
| Blood Pressure Control Following Angiotensin‐Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: Insights from a Triple‐Blind, Randomized, Clinical Trial A Sharifan, M Bahreini, H Ashraf, F Najmeddin The Journal of Clinical Pharmacology 63 (11), 1205-1209, 2023 | 1 | 2023 |
| Conservative and surgical modalities in the management of pediatric parapneumonic effusion and empyema: a living systematic review and network meta-analysis CF Elviro, B Longcroft-Harris, E Allin, L Leache, K Woo, JN Bone, ... Chest, 2023 | 1 | 2023 |
| Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021 V Stein Emil, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, ... Elsevier, 2024 | | 2024 |
| Geographical and Gender Diversity in Cochrane and non-Cochrane Reviews Authorship: A Meta-Research Study A Sofi-Mahmudi, J Stojanova, E Vounzoulaki, E Tomlinson, ... medRxiv, 2024.03. 23.24304672, 2024 | | 2024 |
| Late Breaking Abstract-A living network meta-analysis comparing modalities in the management of pediatric empyema B Longcroft-Harris, E Allin, L Leache, K Woo, JN Bone, C Pawliuk, ... European Respiratory Journal 62 (suppl 67), 2023 | | 2023 |
| For adults with advanced renal cell carcinoma, what are the benefits and harms of first‐line therapy? S Tort, A Sharifan Cochrane Clinical Answers, 2023 | | 2023 |
| How do cephalosporins compare with other antimicrobials for people with enteric fever? A Ciapponi, A Sharifan Cochrane Clinical Answers, 2023 | | 2023 |
| COVID-19 and the Functionality of Antivirals: The Day After Tomorrow A Sharifan Health security 20 (3), 270-271, 2022 | | 2022 |
| How does weekly compare with tri‐weekly paclitaxel with carboplatin for first‐line treatment of women with epithelial ovarian cancer? A Ciapponi, A Sharifan Cochrane Clinical Answers, 2022 | | 2022 |
| How do different therapies compare with placebo and with each other in people with gastrointestinal neuroendocrine tumors (gNETs)? S Tort, A Sharifan Cochrane Clinical Answers, 2022 | | 2022 |
| For women with invasive breast cancer, how do adjuvant capecitabine‐containing and non‐capecitabine‐containing regimens compare? J Burch, A Sharifan Cochrane Clinical Answers, 2022 | | 2022 |
Nassr NamaSeattle Children’s Hospital, University of WashingtonVerified email at seattlechildrens.org
